Treatment of Pseudomonas aeruginosa Infections

First-Line Antipseudomonal Agents

The American College of Physicians recommends piperacillin-tazobactam, ceftazidime, cefepime, and ciprofloxacin as first-line antipseudomonal agents for the treatment of P. aeruginosa infections 1
Ceftazidime is recommended at a dose of 2g IV q8h for the treatment of P. aeruginosa infections 1
Cefepime is recommended at a dose of 2g IV q8-12h for the treatment of P. aeruginosa infections 1
Ciprofloxacin is recommended at a dose of 400mg IV q8h or 750mg PO q12h for the treatment of P. aeruginosa infections 1

For non-severe infections, monotherapy with a highly active β-lactam is generally preferred for susceptible isolates, according to the Infectious Diseases Society of America 1
For severe infections, combination therapy with an antipseudomonal β-lactam and an aminoglycoside or fluoroquinolone is recommended, as per the guidelines of the European Respiratory Society 1, 2
The use of two antipseudomonal drugs may reduce the chance of treatment failure in P. aeruginosa infections, as suggested by the Journal of Microbiology, Immunology and Infection 3

For carbapenem-resistant P. aeruginosa, ceftolozane-tazobactam is recommended as first-line therapy, according to the guidelines of the Infectious Diseases Society of America 4
For multidrug-resistant strains, colistin or polymyxin B are options for highly resistant isolates, as per the recommendations of the European Respiratory Society 1
Combination therapy should be considered to prevent resistance development in multidrug-resistant P. aeruginosa infections, as suggested by the Infectious Diseases Society of America 4, 2

The European Respiratory Society recommends the intravenous route for severe infections and the oral route for less severe infections, if the patient is able to eat 5
The treatment duration for P. aeruginosa infections is typically 7-10 days, but may be extended to 10-14 days for pneumonia or bloodstream infections, as per the guidelines of the Infectious Diseases Society of America 1
For COPD exacerbations with P. aeruginosa, the treatment duration is typically 7-10 days, as recommended by the European Respiratory Society 5

For immunocompromised patients, combination therapy with an antipseudomonal beta-lactam and an aminoglycoside or fluoroquinolone is strongly recommended, according to the guidelines of the Infectious Diseases Society of America 2
Higher doses of antibiotics are often required for patients with cystic fibrosis, as suggested by the European Respiratory Society 6

Fluoroquinolone monotherapy should be avoided for severe infections due to the high risk of resistance development, as per the recommendations of the Infectious Diseases Society of America 2
Aminoglycoside monotherapy should only be considered for uncomplicated urinary tract infections, as suggested by the European Respiratory Society 1
Regular monitoring of aminoglycoside levels is necessary to minimize toxicity while ensuring efficacy, according to the guidelines of the Infectious Diseases Society of America 2